Literature DB >> 15507720

Molecular genetics of DNA viruses: recombinant virus technology.

Bernhard Neuhierl1, Henri-Jacques Delecluse.   

Abstract

Recombinant viral genomes cloned onto BAC vectors can be subjected to extensive molecular genetic analysis in the context of E. coli. Thus, the recombinant virus technology exploits the power of prokaryotic genetics to introduce all kinds of mutations into the recombinant genome. All available techniques are based on homologous recombination between a targeting vector carrying the mutated version of the gene of interest and the recombinant virus. After modification, the mutant viral genome is stably introduced into eukaryotic cells permissive for viral lytic replication. In these cells, mutant viral genomes can be packaged into infectious particles to evaluate the effect of these mutations in the context of the complete genome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15507720     DOI: 10.1385/1-59259-848-x:353

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  20 in total

1.  The Epstein-Barr virus-encoded BILF1 protein modulates immune recognition of endogenously processed antigen by targeting major histocompatibility complex class I molecules trafficking on both the exocytic and endocytic pathways.

Authors:  Jianmin Zuo; Laura L Quinn; Jennifer Tamblyn; Wendy A Thomas; Regina Feederle; Henri-Jacques Delecluse; Andrew D Hislop; Martin Rowe
Journal:  J Virol       Date:  2010-12-01       Impact factor: 5.103

2.  The Epstein-Barr virus BMRF1 gene is essential for lytic virus replication.

Authors:  Bernhard Neuhierl; Henri-Jacques Delecluse
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

3.  The members of an Epstein-Barr virus microRNA cluster cooperate to transform B lymphocytes.

Authors:  Regina Feederle; Janina Haar; Katharina Bernhardt; Sarah D Linnstaedt; Helmut Bannert; Helge Lips; Bryan R Cullen; Henri-Jacques Delecluse
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

4.  The Epstein-Barr virus alkaline exonuclease BGLF5 serves pleiotropic functions in virus replication.

Authors:  R Feederle; H Bannert; H Lips; N Müller-Lantzsch; H-J Delecluse
Journal:  J Virol       Date:  2009-03-04       Impact factor: 5.103

5.  The Epstein-Barr virus protein kinase BGLF4 and the exonuclease BGLF5 have opposite effects on the regulation of viral protein production.

Authors:  Regina Feederle; Anja M Mehl-Lautscham; Helmut Bannert; Henri-Jacques Delecluse
Journal:  J Virol       Date:  2009-08-26       Impact factor: 5.103

Review 6.  Recent advances in cloning herpesviral genomes as infectious bacterial artificial chromosomes.

Authors:  Fuchun Zhou; Shou-Jiang Gao
Journal:  Cell Cycle       Date:  2011-02-01       Impact factor: 4.534

7.  Deletion of Epstein-Barr virus BFLF2 leads to impaired viral DNA packaging and primary egress as well as to the production of defective viral particles.

Authors:  Marisa Granato; Regina Feederle; Antonella Farina; Roberta Gonnella; Roberta Santarelli; Birgit Hub; Alberto Faggioni; Henri-Jacques Delecluse
Journal:  J Virol       Date:  2008-02-20       Impact factor: 5.103

8.  Epstein-Barr viruses that express a CD21 antibody provide evidence that gp350's functions extend beyond B-cell surface binding.

Authors:  Clemens Busse; Regina Feederle; Martina Schnölzer; Uta Behrends; Josef Mautner; Henri-Jacques Delecluse
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

9.  Autoexcision of bacterial artificial chromosome facilitated by terminal repeat-mediated homologous recombination: a novel approach for generating traceless genetic mutants of herpesviruses.

Authors:  Fuchun Zhou; Qiuhua Li; Scott W Wong; Shou-Jiang Gao
Journal:  J Virol       Date:  2010-01-13       Impact factor: 5.103

10.  Expression and processing of a small nucleolar RNA from the Epstein-Barr virus genome.

Authors:  Roland Hutzinger; Regina Feederle; Jan Mrazek; Natalia Schiefermeier; Piotr J Balwierz; Mihaela Zavolan; Norbert Polacek; Henri-Jacques Delecluse; Alexander Hüttenhofer
Journal:  PLoS Pathog       Date:  2009-08-14       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.